Trial watch: IDO inhibitors in cancer therapy
Indoleamine 2,3-dioxygenase 1 (IDO1) catalyzes the first, rate-limiting step of the so-called “kynurenine pathway”, which converts the essential amino acid L-tryptophan (Trp) into the immunosuppressive metabolite L-kynurenine (Kyn). While expressed constitutively by some tissues, IDO1 can also be in...
Main Authors: | Julie Le Naour, Lorenzo Galluzzi, Laurence Zitvogel, Guido Kroemer, Erika Vacchelli |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2020-01-01
|
Series: | OncoImmunology |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/2162402X.2020.1777625 |
Similar Items
-
Trial watch: TLR3 agonists in cancer therapy
by: Julie Le Naour, et al.
Published: (2020-01-01) -
Beyond PD-1 Immunotherapy in Malignant Melanoma
by: Dominika Kwiatkowska, et al.
Published: (2019-03-01) -
Trial watch: STING agonists in cancer therapy
by: Julie Le Naour, et al.
Published: (2020-01-01) -
Trial watch: Dendritic cell-based anticancer immunotherapy
by: Abhishek D. Garg, et al.
Published: (2017-07-01) -
Trial Watch: experimental TLR7/TLR8 agonists for oncological indications
by: Giorgio Frega, et al.
Published: (2020-01-01)